What specific biomarkers will be studied?
The biomarkers being assessed include 4 potential mechanistic / pharmacodynamic markers (Monocyte chemo-attractant protein–1 (MCP-1), Interleukin (IL)-1β, IL-6, IL-17A) and one potential marker of disease progression (C3M)
